Thermo Fisher (TMO) Holder Lathrop Investment Management Lowered Holding by $311,460 as Market Valuation Rose; Sheets Smith Wealth Management Stake in Abiomed (ABMD) Has Upped by $609,000

February 22, 2018 - By mmahotstuff

Lathrop Investment Management Corp decreased its stake in Thermo Fisher (TMO) by 1.93% based on its latest 2017Q3 regulatory filing with the SEC. Lathrop Investment Management Corp sold 1,790 shares as the company’s stock rose 8.13% with the market. The institutional investor held 91,157 shares of the industrial machinery and components company at the end of 2017Q3, valued at $15.90M, down from 92,947 at the end of the previous reported quarter. Lathrop Investment Management Corp who had been investing in Thermo Fisher for a number of months, seems to be less bullish one the $84.77 billion market cap company. The stock increased 0.77% or $1.6084 during the last trading session, reaching $211.3984. About 284,285 shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since February 22, 2017 and is uptrending. It has underperformed by 1.13% the S&P500.

Sheets Smith Wealth Management increased its stake in Abiomed Inc (ABMD) by 161.18% based on its latest 2017Q3 regulatory filing with the SEC. Sheets Smith Wealth Management bought 3,625 shares as the company’s stock rose 15.32% with the market. The institutional investor held 5,874 shares of the health care company at the end of 2017Q3, valued at $990,000, up from 2,249 at the end of the previous reported quarter. Sheets Smith Wealth Management who had been investing in Abiomed Inc for a number of months, seems to be bullish on the $11.73B market cap company. The stock decreased 1.22% or $3.26 during the last trading session, reaching $264.99. About 259,519 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since February 22, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.

Investors sentiment decreased to 1.3 in 2017 Q3. Its down 0.13, from 1.43 in 2017Q2. It turned negative, as 27 investors sold ABMD shares while 89 reduced holdings. 55 funds opened positions while 96 raised stakes. 38.51 million shares or 1.21% less from 38.99 million shares in 2017Q2 were reported. Invesco Ltd holds 180,722 shares or 0.01% of its portfolio. Advsr Asset Incorporated reported 17,968 shares stake. Nicholas Investment Partners LP has invested 0.83% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Great West Life Assurance Communication Can owns 30,836 shares or 0.01% of their US portfolio. State Board Of Administration Of Florida Retirement Sys owns 60,037 shares or 0.03% of their US portfolio. Guggenheim Cap Limited Liability owns 175,298 shares. University Of Notre Dame Du Lac invested in 16,467 shares. Ing Groep Nv has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Geode Cap Lc holds 0.02% or 349,645 shares. Polar Ltd Liability Partnership holds 210,000 shares or 0.4% of its portfolio. Eagle Asset Mgmt has 0.23% invested in ABIOMED, Inc. (NASDAQ:ABMD). Nuveen Asset Mngmt Ltd reported 43,159 shares. Security Natl Trust holds 400 shares. Lpl Ltd Liability Corp accumulated 0.01% or 13,802 shares. 10,648 were accumulated by Messner & Smith Theme Value Mngmt Limited Ca.

Among 14 analysts covering Abiomed (NASDAQ:ABMD), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Abiomed had 33 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Friday, February 2 by Morgan Stanley. As per Friday, October 30, the company rating was upgraded by Raymond James. Guggenheim maintained the stock with “Buy” rating in Friday, February 2 report. The rating was maintained by Piper Jaffray with “Buy” on Thursday, January 4. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Tuesday, June 6 by Jefferies. The firm has “Buy” rating by Jefferies given on Thursday, September 21. The firm earned “Buy” rating on Tuesday, August 18 by Sterne Agee CRT. The company was maintained on Thursday, October 12 by Leerink Swann. The rating was downgraded by BTIG Research to “Neutral” on Monday, October 16. The firm has “Buy” rating given on Thursday, June 8 by William Blair.

Since August 24, 2017, it had 0 buys, and 2 selling transactions for $2.05 million activity. The insider ROSE ERIC A MD sold $142,554.

Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. Thermo Fisher Scientific had 61 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Friday, May 27 by Mizuho. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) earned “Hold” rating by Jefferies on Thursday, July 13. The firm earned “Hold” rating on Friday, October 20 by Jefferies. Cowen & Co maintained it with “Buy” rating and $220.0 target in Wednesday, January 31 report. Deutsche Bank initiated Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday, January 7 with “Buy” rating. The rating was maintained by Jefferies on Wednesday, September 27 with “Hold”. The company was initiated on Tuesday, October 6 by Argus Research. Deutsche Bank maintained the shares of TMO in report on Thursday, October 26 with “Buy” rating. The rating was upgraded by Goldman Sachs to “Americas Conviction Buy List” on Tuesday, December 8. Mizuho maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Tuesday, May 3. Mizuho has “Buy” rating and $163 target.

Since August 28, 2017, it had 0 insider buys, and 9 selling transactions for $21.36 million activity. 6,000 Thermo Fisher Scientific Inc. (NYSE:TMO) shares with value of $1.31 million were sold by Durbin Patrick M. Shares for $721,091 were sold by HORNSTRA PETER E on Tuesday, September 5. 4,140 shares were sold by HOOGASIAN SETH H, worth $736,092. 2,026 shares were sold by Shine Daniel P, worth $366,645. $7.32 million worth of Thermo Fisher Scientific Inc. (NYSE:TMO) was sold by Herrema Gregory J.. Shares for $1.05 million were sold by Williamson Stephen.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>